|
|
News Breaks | | | | January 11, 2013 | | 06:31 EDT |  | SLXP | Salix initiated with an Outperform at RBC Capital
Target $53. | |
|
News For SLXP From The Last 14 Days Check below for free stories on SLXP the last two weeks. |
|
|
| May 22, 2013 | | 07:07 EDT |  | SLXP | Salix announces statistically significant results for budesonide foam
Salix Pharmaceuticals announced the successful completion and outcome of two pivotal Phase 3 studies to evaluate the efficacy and safety of budesonide foam in the treatment of active mild to moderate ulcerative proctitis, UP, or ulcerative proctosigmoiditis, UPS. In each of the two pivotal Phase 3 studies, a statistically significant proportion of subjects treated with budesonide foam achieved clinical remission compared to subjects treated with placebo foam. The company said, “We are pleased with the outcome of our pivotal studies of budesonide foam in the treatment of UP and UPS...We believe foam formulations provide important advantages over enema formulations principally with respect to drug retention and patient acceptance. We are working to submit a New Drug Application for budesonide foam as a treatment for UP and UPS by the end of September 2013. If approved, budesonide foam would be the first foam product approved in the United States for patients with UP...as well as for patients suffering from UPS." | | | May 17, 2013 | | 10:36 EDT |  | SLXP | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
 Subscribe for More Information | | | May 10, 2013 | | 10:00 EDT |  | SLXP | On The Fly: Analyst Downgrade Summary
Subscribe for More Information | | | 08:07 EDT |  | SLXP | Salix price target raised to $57 from $53 at Brean Capital
Subscribe for More Information | | | 06:31 EDT | | SLXP | Salix downgraded to Neutral from Buy at Janney Capital
Subscribe for More Information | | | May 9, 2013 | | 16:10 EDT |  | SLXP | Salix sees 2013 adjusted EPS $3.37, consensus $3.36
Still sees 2013 revenue $920M, consensus $917.9M. | | | 16:09 EDT | | SLXP | Salix reports Q1 adusted EPS 73c, consensus 68c
Reports Q1 revenue $202.6M, consensus $205.94M. | | | 15:27 EDT | | SLXP | Notable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include priceline.com (PCLN), consensus $5.27; Public Storage (PSA), consensus $1.62; NVIDIA (NVDA), consensus 10c; CareFusion (CFN), consensus 53c; Assured Guaranty (AGO), consensus 68c; Medivation (MDVN), consensus (41c); Great Plains Energy (GXP), consensus 12c; Salix Pharmaceuticals (SLXP), consensus 68c; Air Lease (AL), consensus 38c; Sotheby's (BID), consensus (12c). | |
|
|
|
|
|
|
